Traduction de «Common Drug Review » (Anglais → Français) :

Advisory Committee on Pharmaceuticals [ ACP | Common Drug Review Committee | Pharmaceutical Advisory Committee ]

Working in partnerships : drug review for the future : a summary of the review

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

common review procedure

drug-utilization review | DUR | drug-utilization evaluation | DUE

Anti-common-cold drugs

Definition: The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although certain cognitive deficits may evolve in the course of time. The most important psychopathological phenomena include thought echo; thought insertion or withdrawal; thought broadcasting; delusional perception and delusions of control; influence or passivity; hallucinatory voices commenting or discussing the patient in the third person; thought disorders and negative symptoms. The course of schizophrenic disorders can be either continuous, or episodic with progressive or st ...[+++]able deficit, or there can be one or more episodes with complete or incomplete remission. The diagnosis of schizophrenia should not be made in the presence of extensive depressive or manic symptoms unless it is clear that schizophrenic symptoms antedate the affective disturbance. Nor should schizophrenia be diagnosed in the presence of overt brain disease or during states of drug intoxication or withdrawal. Similar disorders developing in the presence of epilepsy or other brain disease should be classified under F06.2, and those induced by psychoactive substances under F10-F19 with common fourth character .5.

prospective DUR | prospective drug-utilization review

retrospective DUR | retrospective drug-utilization review

One of our flagship programs is the Common Drug Review, a federal-provincial- territorial process used to review the clinical effectiveness, cost-effectiveness and patient-group input for new drugs and existing drugs with new indications.

For every drug that we review through the Common Drug Review we have an automatic alert system set up through our electronic information system.

Looking at what the common drug review has or has not achieved, I think people tend to forget, when they criticize the common drug review, that prior to the common drug review each province had some mechanism, as everybody knows.

It further recommended that the federal government collaborate with provincial and territorial governments through the common drug review to make approved medications for Alzheimer's disease and related dementias accessible to all Canadians in all provinces by ensuring these drugs are part of provincial drug formularies and that the criteria to assess them are appropriate and consistent, meaning from hospitals, long term care institutions and home care, et cetera.